You are here

Approvals, Launches, and New Indications

Regimen showed significant improvement in overall survival in trial versus Sutent
Drug is first and only approved specific reversal agent for a novel oral anticoagulant
Test performed in the primary care setting may improve access to screening
Lenses automatically darken in bright light
Agent is now approved for the maintenance treatment of recurrent disease regardless of BRCA status
Approval streamlines review pathway for similar devices
First approved agent for patients who are in remission but have minimal residual disease
New pen can potentially reduce the number of injections and lower copay costs
How will it impact the competition?
Option approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema